Radiopharmaceutical experts urge pharma to adopt bolder dosing despite safety concerns

Louise Emmett and a group of radiopharmaceutical specialists argue that these modern radiation‑based drugs could dramatically improve cancer outcomes if used more aggressively. They say the therapies have the potential to destroy tumors and extend patient survival, especially when administered more frequently than current protocols allow.

However, developers have encountered safety issues, with some experimental agents affecting the kidneys, liver, or bone marrow. These toxicities have already forced at least one company to cease operations and have created challenges for others in the field.

Emmett, who collaborates with major drugmakers such as AstraZeneca and Novartis, contends that the industry’s caution is excessive given the promise of radiopharmaceuticals. She calls for a more daring approach to dosing while still managing the identified risks.

The article highlights a tension between the desire to accelerate innovative cancer treatments and the need to safeguard patient safety, suggesting that a balanced strategy will be essential for the sector’s growth.